MedCity News covered Nexo's launch, financing and research alliance with MD Anderson, emphasizing the company's strategy to broaden the amino acids addressable by covalent chemistry.
MedCity News covered Nexo’s launch by focusing on the company’s strategy to expand the scope of amino acids that can be addressed by covalent chemistry in cancer drug research. The article paired the $60 million financing with Nexo’s collaboration with MD Anderson and positioned the platform as a way to pursue targets that have often been labeled difficult to drug.
The story also highlighted Andrew Phillips’ view that covalency can provide the starting point needed to optimize leads, while noting that Nexo aims to be broader than companies built around a single amino acid chemistry. It described the platform as combining hit discovery at scale with biological insight into how deeply and how long a target needs to be inhibited.
Original coverage: MedCity News